ARID2 and neoplasm: To investigate the tumor-specific CD8+ T cell response, we isolated CD8+ T cells on day 8 after ACT and observed a significant increase in the frequency and cell number of Arid2-deficient CD8+ P14 cells in the tumor and draining lymph nodes (Figures 7B–7D, S6A, and S6B).